Notice of Preliminary Results: Date Change

RNS Number : 2051I

Ergomed plc

20 March 2018

 

PRESS RELEASE

Notice of Preliminary Results: Date Change

London, UK - 20 March 2018: Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a specialised pharmaceutical services and drug development company, announces that the Company will publish its Preliminary Results for the year ending 31 December 2017 on 11 April 2018.

Stephen Stamp, Chief Executive Officer, will host a presentation and conference call for analysts at 9:30am BST on the day of the results at the offices of Numis Securities, The London Stock Exchange Building, 10 Paternoster Square, London, EC4M 7LT.

- ENDS -

Enquiries:

Ergomed plc		Tel: [phone]
Stephen Stamp (Chief Executive Officer)
Numis Securities Limited		Tel: [phone]
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black (Joint Broker)
N+1 Singer		Tel: [phone]
Alex Price (Joint Broker)
Consilium Strategic Communications - for UK enquiries		Tel: [phone]
Chris Gardner / Mary-Jane Elliott Ivar Milligan / Philippa Gardner	[e-mail]
MC Services - for Continental European enquiries		Tel: [phone]
Anne Hennecke

About Ergomed

Ergomed provides specialist services to the pharmaceutical industry and develops drugs both wholly-owned and through partnerships. Ergomed's fast-growing, profitable service offering spans all phases of clinical development and post-approval pharmacovigilance and medical information. Drawing on more than 20 years of expertise in drug development, Ergomed is also building a growing portfolio of drug development partnerships and programmes, including wholly-owned proprietary products for the treatment of surgical bleeding. For further information, visit: http://ergomedplc.com.

 

END

 

 

NORSFSFWUFASEDD